U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07132333) titled 'Molecular Inflammation Board at the Center for Personalized Medicine' on Aug. 11.

Brief Summary: Molecular Inflammation Board at the Center for Personalized Medicine

Study Start Date: Nov. 16, 2022

Study Type: OBSERVATIONAL

Condition: Psoriasis (PsO) Psoriasis Arthritis Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) Spondylarthropathies

Intervention: BIOLOGICAL: Biologic Agent

Intervention with biologic agents

Recruitment Status: RECRUITING

Sponsor: University Hospital Tuebingen

Published by HT Digital Content Services with permission from Health Daily Digest....